NRSNW
OtherNeuroSense Therapeutics Ltd. Warrant
Live · NASDAQ · May 13, Close
What's Moving NRSNW Today?
No stock-specific AI insight has been generated for NRSNW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.20
Fundamentals
Trading
NRSNW News
13 articles- NeuroSense Announces Pricing of Insider-Led PIPE FinancingYahoo Finance·Apr 28, 2026
- NeuroSense Granted Brazilian Patent Covering PrimeC CompositionYahoo Finance·Apr 6, 2026
- NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value RequirementsYahoo Finance·Apr 3, 2026
- NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 31, 2026
- NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's ReadoutYahoo Finance·Mar 24, 2026
- /C O R R E C T I O N -- NeuroSense/Yahoo Finance·Mar 18, 2026
- NeuroSense to Host Investor Webinar on December 8, 2025Yahoo Finance·Nov 3, 2025
- NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease BiomarkersYahoo Finance·Oct 6, 2025
- Sector Update: Health Care Stocks Retreat Late AfternoonYahoo Finance·Sep 10, 2025
- NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived NeuronsYahoo Finance·Sep 10, 2025
- NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market PriceYahoo Finance·Sep 4, 2025
- NeuroSense Provides Business Update and Progress for the First Half of 2025Yahoo Finance·Aug 1, 2025
- Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and CommunityYahoo Finance·Jul 22, 2025
All 13 articles loaded
Price Data
52-Week Range
$0.20
Fundamentals
Trading
About NeuroSense Therapeutics Ltd. Warrant
NeuroSense Therapeutics Ltd. is a pioneering biotechnology company dedicated to advancing innovative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company’s lead candidate strategically targets the underlying mechanisms of disease progression, aiming to provide transformative treatment solutions for patients. Utilizing a multi-modal approach that integrates diverse therapeutic strategies, NeuroSense distinguishes itself in the competitive neurotherapeutics sector. Committed to robust clinical development and scientific rigor, NeuroSense is poised to make impactful contributions to the biopharmaceutical field and enhance treatment options for those suffering from debilitating neurological disorders.